» Articles » PMID: 24894701

Treatment with a Nicotine Vaccine Does Not Lead to Changes in Brain Activity During Smoking Cue Exposure or a Working Memory Task

Overview
Journal Addiction
Specialty Psychiatry
Date 2014 Jun 5
PMID 24894701
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Aims: To assess whether immunization attenuates nicotinic stimulation of the brain and elucidate brain and behavioural responses during exposure to smoking cues and a working memory task.

Design: Randomized, placebo-controlled parallel-group, repeated-measures design.

Setting: Maastricht University, the Netherlands.

Participants: Forty-eight male smokers were randomized to receive five injections with either 400 μg/ml of the 3'-aminomethylnicotine Pseudomonas aeruginosa r-Exoprotein-conjugated vaccine or placebo. Subjects were tested on two occasions, once after a nicotine challenge and once after a placebo challenge, and were asked to refrain from smoking 10 hours before testing.

Measurements: Reaction-times and accuracies were recorded during an n-back task. Moreover, regional blood oxygenated level-dependent (BOLD) response was measured during this task and during smoking cue exposure.

Findings: Greater activation was found in response to smoking cues compared to neutral cues in bilateral trans-occipital sulcus (P < 0.005); however, this effect did not survive correction for multiple comparisons. There was no difference in brain activity to smoking cues between the treatment groups and no effects of acute nicotine challenge were established. For the n-back task we found working memory load-sensitive increases in brain activity in several frontal and parietal areas (P < 0.0025). However, no effects of immunization or nicotine challenge were observed.

Conclusion: No significant effects of immunization on brain activity in response to a nicotine challenge were established. Therefore this vaccine is not likely to be an effective aid in smoking cessation.

Citing Articles

Cue-reactivity targeted smoking cessation intervention in individuals with tobacco use disorder: a scoping review.

Luo M, Gan Q, Fu Y, Chen Z Front Psychiatry. 2023; 14:1167283.

PMID: 37743997 PMC: 10512743. DOI: 10.3389/fpsyt.2023.1167283.


Vaccines as a preventive tool for substance use disorder: A systematic review including a meta-analysis on nicotine vaccines' immunogenicity.

Scendoni R, Bury E, Ribeiro I, Cameriere R, Cingolani M Hum Vaccin Immunother. 2022; 18(6):2140552.

PMID: 36351881 PMC: 9746524. DOI: 10.1080/21645515.2022.2140552.


Vaccines against Drug Abuse-Are We There Yet?.

Bloom B, Bushell M Vaccines (Basel). 2022; 10(6).

PMID: 35746468 PMC: 9230984. DOI: 10.3390/vaccines10060860.


Current Trends and Perspectives in the Immune Therapy for Substance Use Disorders.

Vasiliu O Front Psychiatry. 2022; 13:882491.

PMID: 35573367 PMC: 9095939. DOI: 10.3389/fpsyt.2022.882491.


Leveraging the interplay of nanotechnology and neuroscience: Designing new avenues for treating central nervous system disorders.

Smith E, Porterfield J, Kannan R Adv Drug Deliv Rev. 2019; 148:181-203.

PMID: 30844410 PMC: 7043366. DOI: 10.1016/j.addr.2019.02.009.